Gilead cannot survive competition from LL in cance
Post# of 148151
(Total Views: 525)
Posted On: 08/27/2021 5:08:59 PM
Gilead cannot survive competition from LL in cancer and HIV.
Gilead has one of the highest DtE ration in the industry.
NAS:GILD's Debt-to-Equity is ranked lower than
92% of the 905 Companies
in the Drug Manufacturers industry.
( Industry Median: 0.22 vs. NAS:GILD: 1.53 )
This is why our biggest problem might be not so much the FDA/BP cabal as those TBTF banks who own their debt. They are the real power.
Gilead has one of the highest DtE ration in the industry.
NAS:GILD's Debt-to-Equity is ranked lower than
92% of the 905 Companies
in the Drug Manufacturers industry.
( Industry Median: 0.22 vs. NAS:GILD: 1.53 )
This is why our biggest problem might be not so much the FDA/BP cabal as those TBTF banks who own their debt. They are the real power.
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
Scroll down for more posts ▼